Repligen Corporation introduced three new chromatography resins on December 16, 2025: AVIPure® HiPer™ AAV9, AVIPure® HiPer™ AAV8, and HiPer™ QA anion‑exchange resin. The resins are built on the Tantti™ DuloCore™ base bead technology that Repligen acquired in July 2024, a platform that delivers faster processing and robust performance for viral vector and anion‑exchange purification workflows.
The AAV9 and AAV8 resins target the expanding gene‑therapy market, offering higher yields and improved molecule stability for adeno‑associated virus vector manufacturing. The HiPer™ QA resin expands Repligen’s Proteins portfolio into a key purification step for a broader range of biologics, including antibody‑drug conjugates and other next‑generation modalities.
"Gene therapy manufacturers need scalable, high‑performance solutions. Our latest AAV8 and AAV9 resins, along with our HiPer QA anion‑exchange resin, are designed to deliver significantly faster processing and robust performance across today’s increasingly complex biotherapeutic workflows," said Umay Saplakoğlu, Vice President of Proteins and Incubator at Repligen.
Repligen’s Q3 2025 results—revenue of $189 million, up 22 % year‑over‑year, and an adjusted EPS of $0.46—demonstrate the company’s strong execution and growing demand for its bioprocessing solutions. The company raised its full‑year guidance following the quarter, reflecting confidence in continued growth and margin expansion.
The new resins are part of Repligen’s strategy to capture higher‑margin segments and accelerate product development for gene‑therapy developers. The company anticipates broader chromatography resin launches in 2026, further integrating Tantti technology and expanding its presence in the next‑generation biologics space. Together, these moves reinforce Repligen’s position as a pure‑play bioprocessing specialist and broaden its addressable market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.